Kabra Drugs Limited Announces FY26 Audited Results

Kabra Drugs Limited reported a net profit of ₹4.96 crore for the financial year ended March 31, 2026. This marks a significant turnaround from a net loss of ₹1.09 crore in the previous fiscal year. Revenue from operations for FY26 stood at ₹92.74 crore.

Reader Takeaway: Profitable FY26 turnaround; watch for working capital surge.

What just happened

Kabra Drugs Limited has announced its audited financial results for the fiscal year 2025-26. The company achieved a net profit of ₹4.96 crore, a considerable improvement from the net loss of ₹1.09 crore reported in FY25. Total revenue for the year was ₹92.74 crore.

The company also noted that its financial performance was impacted by a transition to the concessional tax regime under Section 115BAA of the Income-tax Act, 1961, affecting its current tax expense.

Why this matters

This shift to profitability is a key indicator of improved operational performance and financial health for Kabra Drugs. The turnaround suggests that the company's strategies may be yielding positive results. The impact of the tax regime change is also a crucial factor for understanding the profit figure.

The backstory

In the previous fiscal year, FY25, Kabra Drugs had reported a net loss of ₹1.09 crore. The current year's profit of ₹4.96 crore represents a strong recovery and a reversal of that trend.

What changes now

Investors will be looking for sustained profitability in the coming quarters. The significant increase in trade receivables to ₹70.78 crore and trade payables to ₹54.83 crore indicates a potential expansion or change in business operations. The company also implemented Ind AS 116 (Leases), leading to accounting adjustments for depreciation, finance costs, and rent expenses.

Risks to watch

The sharp rise in trade receivables and trade payables warrants attention. Investors need to monitor the company's ability to collect these receivables and manage its payment cycles to ensure healthy cash flow and avoid potential credit risks.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Net Profit (FY26): ₹4.96 crore (Turnaround from ₹-1.09 crore in FY25)
• Revenue (FY26): ₹92.74 crore
• Trade Receivables (FY26): ₹70.78 crore (vs. ₹0.60 crore in FY25)
• Trade Payables (FY26): ₹54.83 crore (vs. ₹0 in FY25)

What to track next

Investors should closely track the company's cash flow statements, receivable days, and payable days in future quarterly results to understand the impact of the working capital changes. Monitoring management's commentary on sales, collections, and supplier payments will be crucial.